A Phase II Clinical Study Evaluating the Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury
Latest Information Update: 22 May 2025
At a glance
- Drugs XS 228 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
Most Recent Events
- 22 May 2025 New trial record